CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: A humanized anti-CD4 depleting antibody has already demonstrated efficacy in patients with cutaneous T cell lymphoma [45], although its usefulness as immunotherapy against solid tumors remains to be explored.